iOnctura SA logo

iOnctura SA

iOnctura is a late pre-clinical stage biopharma company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. iOnctura is developing a pipeline of carefully selected assets that target and modulate mechanisms that drive immuno-suppression in the tumour microenvironment (TME).

iOnctura is an immuno-oncology spin-out company formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). The creation of iOnctura and its future investments will be facilated by Merck Ventures.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.ionctura.com
Founded2017
Disease Focus
Development StagePreclinical
STOCK CODENon Listed
Address
Campus Biotech Innovation ParkB_timent F2Avenue S_cheron 151202
Genve
Switzerland
Email
info@iOnctura.com
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/ioncturasa/about” connections=”true” suffix=””]

In Jun 2017, Cancer Research UKs Cancer Research Technology (CRT) grants Mercks newly-created iOnctura options to exclusive, worldwide rights to three immuno-oncology assets, In exchange, iOnctura provided CRT with an initial equity holding in the company and will make further payments for the achievement of late development and approval milestones as well as royalties on net sales.